Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group..

Lancet. 2002 Jun 15;359(9323):2072-7.

PMID:
12086760
3.

Efficacy of acarbose in Chinese subjects with impaired glucose tolerance.

Pan CY, Gao Y, Chen JW, Luo BY, Fu ZZ, Lu JM, Guo XH, Cheng H.

Diabetes Res Clin Pract. 2003 Sep;61(3):183-90.

PMID:
12965108
4.

Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group..

Diabetologia. 2004 Jun;47(6):969-75; discussion 976-7. Epub 2004 May 26.

PMID:
15164169
6.

Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.

Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL.

Diab Vasc Dis Res. 2009 Jan;6(1):32-7. doi: 10.3132/dvdr.2009.006.

PMID:
19156626
7.

[Progress in the prevention of type 2 diabetes].

Schernthaner G.

Wien Klin Wochenschr. 2003 Nov 28;115(21-22):745-57. Review. German.

PMID:
14743578
8.

Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.

Koyasu M, Ishii H, Watarai M, Takemoto K, Inden Y, Takeshita K, Amano T, Yoshikawa D, Matsubara T, Murohara T.

Clin Ther. 2010 Aug;32(9):1610-7. doi: 10.1016/j.clinthera.2010.07.015.

PMID:
20974318
9.

Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy.

Zeymer U, Schwarzmaier-D'assie A, Petzinna D, Chiasson JL; STOP-NIDDM Trial Research Group..

Eur J Cardiovasc Prev Rehabil. 2004 Oct;11(5):412-5.

PMID:
15616415
10.

Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.

Zeymer U.

Int J Cardiol. 2006 Feb 8;107(1):11-20. Review.

PMID:
16337493
12.

Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.

Quilici S, Chancellor J, Maclaine G, McGuire A, Andersson D, Chiasson JL.

Int J Clin Pract. 2005 Oct;59(10):1143-52.

PMID:
16178980
13.

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.

Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T.

Stroke. 2004 May;35(5):1073-8. Epub 2004 Apr 8.

14.

A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI).

Nijpels G, Boorsma W, Dekker JM, Kostense PJ, Bouter LM, Heine RJ.

Diabetes Metab Res Rev. 2008 Nov-Dec;24(8):611-6. doi: 10.1002/dmrr.839.

PMID:
18756586
15.
16.

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

Holman RR, Bethel MA, Chan JC, Chiasson JL, Doran Z, Ge J, Gerstein H, Huo Y, McMurray JJ, Ryden L, Liyanage W, Schröder S, Tendera M, Theodorakis MJ, Tuomilehto J, Yang W, Hu D, Pan C; ACE Study Group..

Am Heart J. 2014 Jul;168(1):23-9.e2. doi: 10.1016/j.ahj.2014.03.021. Epub 2014 Apr 5.

PMID:
24952856
17.

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.

Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005061. Review.

PMID:
17054235
18.

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group..

JAMA. 2003 Jul 23;290(4):486-94.

PMID:
12876091
20.

[Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].

Sakamoto N, Tajima N.

Nihon Rinsho. 2005 Feb;63 Suppl 2:451-6. Review. Japanese. No abstract available.

PMID:
15779421

Supplemental Content

Support Center